📊 AVAI Key Takeaways
Is Avai Bio, Inc.. (AVAI) a Good Investment?
AVAI Bio exhibits severe financial distress with negative stockholders' equity of -$2.8M, indicating the company is technically insolvent. The company is burning cash at an unsustainable rate (-$959K operating cash flow) while generating minimal revenue ($276.3K) with negative gross margins, suggesting fundamental business model failure.
AVAI BIO, INC. shows extremely weak fundamentals, with negative gross profit, deeply negative operating and net margins, and operating losses that far exceed its revenue base. Financial health is severely impaired by minimal cash, a current ratio of 0.02x, negative equity, and sustained negative operating cash flow, indicating a high risk that the business cannot fund itself without external support.
Why Buy Avai Bio, Inc.. Stock? AVAI Key Strengths
- Minimal debt obligations provide some operational flexibility
- Early-stage company status may allow for strategic pivots
- Positive revenue generation exists despite losses
- The company is generating some revenue rather than operating at zero sales
- Net loss is smaller than operating loss, suggesting some non-operating offset or accounting support
- Asset-light structure may allow faster cost restructuring if management can materially reduce expenses
AVAI Stock Risks: Avai Bio, Inc.. Investment Risks
- Negative stockholders' equity indicates technical insolvency and imminent going concern issues
- Severe liquidity crisis with current ratio of 0.02x and only $50.4K cash against $3.0M liabilities
- Catastrophic unit economics with -$3.46 of cash burn for every $1 of revenue generated
- Negative gross margins indicate products/services are losing money at point of sale
- Unsustainable cash burn rate of -$959K with current cash reserves lasting approximately 2 weeks
- Gross margin is negative, indicating the core business is not currently profitable even before overhead
- Liquidity is critically weak, with only $50.40K in cash against a heavily stressed balance sheet
- Negative equity and persistent cash burn raise substantial going-concern and dilution risk
Key Metrics to Watch
- Cash runway and path to profitability or capital raise
- Revenue growth trajectory and gross margin improvement
- Monthly cash burn rate and covenant compliance status
- Operating cash flow burn relative to cash on hand
- Improvement in gross margin and current ratio
Avai Bio, Inc.. (AVAI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
AVAI Profit Margin, ROE & Profitability Analysis
AVAI vs Technology Sector: How Avai Bio, Inc.. Compares
How Avai Bio, Inc.. compares to Technology sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Avai Bio, Inc.. Stock Overvalued? AVAI Valuation Analysis 2026
Based on fundamental analysis, Avai Bio, Inc.. has mixed fundamental signals relative to the Technology sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Avai Bio, Inc.. Balance Sheet: AVAI Debt, Cash & Liquidity
AVAI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Avai Bio, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.02 indicates the company is currently unprofitable.
AVAI Revenue Growth, EPS Growth & YoY Performance
Avai Bio, Inc.. Dividends, Buybacks & Capital Allocation
AVAI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Avai Bio, Inc.. (CIK: 0001740797)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AVAI
What is the AI rating for AVAI?
Avai Bio, Inc.. (AVAI) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AVAI's key strengths?
Claude: Minimal debt obligations provide some operational flexibility. Early-stage company status may allow for strategic pivots. ChatGPT: The company is generating some revenue rather than operating at zero sales. Net loss is smaller than operating loss, suggesting some non-operating offset or accounting support.
What are the risks of investing in AVAI?
Claude: Negative stockholders' equity indicates technical insolvency and imminent going concern issues. Severe liquidity crisis with current ratio of 0.02x and only $50.4K cash against $3.0M liabilities. ChatGPT: Gross margin is negative, indicating the core business is not currently profitable even before overhead. Liquidity is critically weak, with only $50.40K in cash against a heavily stressed balance sheet.
What is AVAI's revenue and growth?
Avai Bio, Inc.. reported revenue of $276.3K.
Does AVAI pay dividends?
Avai Bio, Inc.. does not currently pay dividends.
Where can I find AVAI SEC filings?
Official SEC filings for Avai Bio, Inc.. (CIK: 0001740797) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AVAI's EPS?
Avai Bio, Inc.. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AVAI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Avai Bio, Inc.. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AVAI stock overvalued or undervalued?
Valuation metrics for AVAI: ROE of N/A (sector avg: 22%), net margin of -200.4% (sector avg: 18%). Compare these metrics with sector averages to assess valuation.
Should I buy AVAI stock in 2026?
Our dual AI analysis gives Avai Bio, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AVAI's free cash flow?
Avai Bio, Inc..'s operating cash flow is $-959.0K, with capital expenditures of N/A. FCF margin is -347.1%.
How does AVAI compare to other Technology stocks?
Vs Technology sector averages: Net margin -200.4% (avg: 18%), ROE N/A (avg: 22%), current ratio 0.02 (avg: 2.5).